Filing Flows › UroGen Pharma (URGN) › Q1 2026
UroGen Pharma (URGN) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
UroGen Pharma (URGN) reported revenue of $51.0M for the first quarter 2026 (Q1 2026), +152% from a year earlier and +35% from the quarter before. Operating margin was -39.8%, net loss $23.6M (46.3% of revenue).
UroGen Pharma, Q1 2026: revenue $51.0M (+152% year over year), operating margin -39.8%, net loss $23.6M, operating cash flow −$45.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $51.0M | +35% | +152% |
| Operating profit | −$20.3M | — | — |
| Net earnings | −$23.6M | — | — |
| Operating cash flow | −$45.3M | — | — |
What changed
Revenue was $51.0M in Q1 2026, up 152% year over year and up 35% from the previous quarter. Zusduri was the largest line at 57% of revenue. Jelmyto added $1.5M year over year (up 7%), 5% of the total change.
Gross margin was 91.9%, up 3.4 points from Q1 2025. Operating costs exceeded revenue by $20.3M, an operating margin of -39.8%. Operating expenses grew 22% against revenue growth of 152%. The fastest-growing cost line was SG&A (+47%). The quarter ended with a net loss of $23.6M, narrower than the previous quarter's $26.4M loss.
Operating cash flow was −$45.3M. Non-cash charges added back $75K of depreciation and amortization and $4.6M of share-based compensation. Working capital and other items used $26.4M. Capital expenditures of $54K exceeded it, leaving free cash flow of −$45.4M.
Questions
What was UroGen Pharma's revenue in the first quarter 2026?
UroGen Pharma (URGN) reported revenue of $51.0M for the first quarter 2026 (Q1 2026), +152% from a year earlier and +35% from the quarter before.
Was UroGen Pharma profitable in the first quarter 2026?
Operating loss was $20.3M (-39.8% of revenue) and net loss $23.6M.
Source: UroGen Pharma 10-Q on SEC EDGAR.